As far as organoid manufacturing is concerned, bioprinting technology streamlines the making and maintenance of complicated biological 3D shapes and structures and enables standardization and quality control at the time of production.
Standardized organoids produced by bioprinting combined with artificial intelligence promise to replace experimental animals as disease models and for drug screening. Image Credit: Cyborg and Bionic Systems
The addition of artificial intelligence, which could validate the product potential in the manufacturing process, enables a highly standardized source of cells for the organoid concerning function, viability, etc.
Alternatively, bioprinting integrated with artificial intelligence has been anticipated to execute real-time diagnostics of organoids and eventually achieve high-quality homogenized in vitro models.
Professor Hyungseok Lee, from the Department of Mechanical and Biomedical Engineering at Kangwon National University, presented his viewpoints on the future progress of organoid manufacturing on March 6th, 2023, in the journal Cyborg and Bionic Systems.
Organoids that have the potential to self-organize and assemble consist of an extensive range of research and application outlooks. Besides the majority of the fundamental simulation of human organ development that could not be studied in animal models, organoids could also replicate human pathology rather than animals to finish the research.
Due to the comfortable customization of cell sources, organoids can be utilized as “stand-ins” for clinical patients to personally anticipate the best therapeutic agents.
Such an extensively utilized organoid is experiencing the hardships of standardizing its production. As a result of the differences in culture, experimenter, and cellular conditions, the organoid, while allowing disease modeling, loses the potential to exhibit rigorously consistent properties for application in screening new drugs, particularly in the process of quantification.
Retaining all nutrients, growth factors, and metabolites in constant equilibrium is a technical difficulty during organoid growth. This could lead to discrepancies with the actual target tissue.
Bioprinting, particularly extrusion bioprinting, allows standardized manufacturing of organoid components with complicated cellular composition and structure, regulating the quality and reducing human intervention.
Bioprinting technology could also assist in the automation of manufacturing processes. High resolution is the vital key for bioprinting organoids, which has been anticipated to identify the fabrication of vascularized organoids with perfusion networks and defeat the restriction of passive transport of substances.
Artificial intelligence is gaining huge attention for its potential to track and regulate the quality of the eventual exploited object.
The bioprinting process applies to make organoids track cell status and printed structures in real-time, offering feedback for fine printing to guarantee resolution. This is the future direction of this type of organ manufacturing prospects for modeling complicated diseases and combinatorial testing of new drugs.
Journal Reference:
Lee, H., (2023) Engineering In vitro Models: Bioprinting of Organoids with Artificial Intelligence. Cyborg and Bionic Systems. doi.org/10.34133/cbsystems.0018.